Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine in Japanese subjects with advanced malignancies
NCT02485119Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2015
- Primary completion
- Apr 2017
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of anetumab ravtansine in solid tumor (2 cohorts), sponsored by Bayer. Primary endpoints: Number of Treatment-emergent Adverse Events up to 9 weeks, Intensity of TEAEs acc. to NCI CTCAE v.4.03 up to 9 weeks and 3 more. Started Aug 2015; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02485119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485119.